DEC-C Post-Transplant

A Phase I/II Trial of Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1/2
Enrollment
126 patients (estimated)
Sponsors
Washington University School of Medicine
Collaborators
Taiho Oncology, Inc.
Tags
Chemotherapy, Cytidine Deaminase Inhibitor (CDAi), Minimal Residual Disease (MRD), Post-Allogeneic Stem Cell Transplant
Trial Type
Treatment
Last Update
1 month ago
SparkCures ID
1513
NCT Identifier
NCT04742634

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.